Abstract:Background: Type 2 diabetes mellitus (T2DM) known as non-insulin-dependent diabetes mellitus, which is increasingly acknowledged as being associated with an increased risk for a series of cancers. Pancreatic cancer is currently the fourth most common cause of cancer-related mortality, which has been proved to be worsened by internal diabetic condition. However, the underlying molecular mechanisms are less addressed. Furthermore, current knowledge revealed that therapeutic strategy by anti-diabetes for pancreatic cancer under diabetes condition have no satisfactory efficacy, and nor by chemotherapy in our study.Methods: To clarify these mysteries and widen our knowledge, both obesity-associated and non-obese-associated T2DM mouse models were generated by chemical induction with streptozotocin (STZ) and leptin receptor knockout (db/db) in mice. Then, the process of tumor progression was researched, and the gene expression profiling of pancreatic cancer in mice was performed using RNA-seq.Results: Our results showed that pancreatic cancer malignancy was increased with notable proliferation and metastatic potential in two diabetic mice model. Totally, 136 and 64 significantly differentially expressed genes (DEGs) were identified in STZ and db/db mice by transcriptomic analysis. The results also suggested that different carcinogenesis-related genes and potential molecular mechanisms contribute to the malignancy of pancreatic cancer in obesity-associated and non-obesity-associated T2DM. In obesity-associated db/db mice, the GO subcategories associated with most of the genes with downregulated expression are involved in the immune response. However, in non-obesity-associated STZ mice, in addition to the immune response category, the enriched subcategories also included angiogenesis and the extracellular matrix. While, two genes respectively encoding MMP-2 and MMP-9 were simultaneously abnormal up-regulated in pancreatic cancer tissue from diabetic mice of both STZ and db/db, that could act as potential therapeutic targets for significantly suppressing the malignant progression. Furthermore, an optimizing therapeutic strategy was further proposed that combining MMP-2/9 inhibitor with gemcitabine significantly enhanced anti-tumor effects on pancreatic cancer under diabetic condition, providing a theoretical basis for clinical applications.Conclusions: Generally, this study provides a comprehensive insight into diabetes as a risk factor for pancreatic cancer and has the potential to guide the development of enhanced treatment strategies.

Unraveling the biological link between diabetes mellitus and prostate cancer: Insights and implications

The association between diabetes mellitus and prostate cancer: a meta-analysis and Mendelian randomization

Why does diabetes offer protective effects against prostate cancer? The possible role of its microvascular complications

Diabetes Mellitus and Pancreatic Cancer: Investigation of Causal Pathways Through Mendelian Randomization Analysis

Association of Diabetes Mellitus with Prostate Cancer Grade and Prostate-Specific Antigen in Chinese Biopsy Population

Diabetes and cancer: Epidemiological and biological links

Diabetes mellitus reduces prostate cancer risk - no function of age at diagnosis or duration of disease.

Diabetes Mellitus and Prostate Cancer Risk—A Systematic Review and Meta-Analysis

Diabetes causes multiple genetic alterations and downregulates expression of DNA repair genes in the prostate

Semen As a Rich Source of Diagnostic Biomarkers for Prostate Cancer: Latest Evidence and Implications

Obesity, diabetes mellitus, and pancreatic carcinogenesis: Correlations, prevention, and diagnostic implications

Effects of Diabetes Mellitus and Metformin Administration on Prostate Cancer Detection at Biopsy among Chinese Men: a Case-Control Study.

Diabetes Mellitus and Incidence and Mortality of Colorectal Cancer: a Systematic Review and Meta-Analysis of Cohort Studies

[Mendelian randomization of diabetes and prostate cancer risk in East Asian population]

Identification of Proteins Implicated in the Development of Pancreatic Cancer-Associated Diabetes Mellitus by Itraq-Based Quantitative Proteomics.

Diabetes Mellitus and Prostate Cancer Risk of Different Grade or Stage: A Systematic Review and Meta-Analysis

Peripheral Coagulation Parameters and Prostate Cancer Association: A Retrospective Study and Mendelian Randomization

The relationship between immune cells and prostate cancer, and the mediating role of metabolites: a Mendelian randomization study

Diabetes and pancreatic cancer: Exploring the two-way traffic

Diabetes Mellitus And Risk Of Bladder Cancer: A Meta-Analysis Of Cohort Studies

Transcriptomic Analyses and Potential Therapeutic Targets of Pancreatic Cancer With Concomitant Diabetes